Department of Clinical Medicine & Surgery, Federico II University, Naples, 80131, Italy.
Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037, Italy.
Biomark Med. 2024;18(8):357-361. doi: 10.2217/bmm-2023-0801. Epub 2024 Apr 16.
Two recent articles by the same research group documented that patients with severe eosinophilic asthma exhibit an increased proportion of a subtype of eosinophils, namely CD62L inflammatory eosinophils (iEos) and identified an intriguing correlation between such iEos and asthma control scores. Moreover, CD62L iEos were reduced after treatment with the anti-IL-5 monoclonal antibody mepolizumab. In the future, we believe that eosinophil subtypes could represent a useful biomarker in severe eosinophilic asthma, helping clinicians characterize patient endotypes and monitoring the response to biological drugs.
两篇来自同一研究团队的最新文章指出，严重嗜酸性粒细胞性哮喘患者表现出一种嗜酸性粒细胞亚型的比例增加，即 CD62L 炎症性嗜酸性粒细胞（iEos），并确定了这种 iEos 与哮喘控制评分之间的有趣相关性。此外，抗 IL-5 单克隆抗体美泊利珠单抗治疗后 CD62L iEos 减少。我们相信，嗜酸性粒细胞亚型在严重嗜酸性粒细胞性哮喘中可能代表一种有用的生物标志物，有助于临床医生描述患者的表型，并监测对生物药物的反应。
